Background: Data is limited evaluating novel biomarker and right ventricular dysfunction. Normal right ventricular function (RVF) improves the prognosis of patients suffering from heart failure. Therefore, the study investigates the association between the biomarker copeptin and right heart function compared to NT-proBNP.

Methods: Patients undergoing echocardiography were enrolled prospectively. RVF was assessed by TAPSE, right ventricular and atrial parameters. Exclusion criteria were age under 18 years, LVEF < 50 % and moderate to severe valvular heart disease. Blood samples were taken for measurements within 72 hours of echocardiography.

Results: 91 patients were included. Median values of copeptin increased significantly according to decreasing values of TAPSE (p = 0.001; RVF grade I: Tricuspid annular plane systolic excursion; TAPSE > 24 mm: 5.20 pmol/l; grade II: TAPSE 18 - 24 mm: 8.10 pmol/l; grade III: TAPSE < 18 mm: 26.50 pmol/l). Copeptin levels were able to discriminate patients with decreased right ventricular function defined as TAPSE < 18 mm (area under the curves (AUC): copeptin: 0.793; p = 0.001; NT-proBNP: 0.805; p = 0.0001). Within a multivariate linear regression model copeptin was still independently associated with TAPSE (copeptin: T: -4.43; p = 0.0001; NT-proBNP: T: -1.21; p = 0.23). Finally, copeptin levels were significantly associated with severely decreased RVF (TAPSE < 18 mm) within a multivariate logistic regression model (copeptin: odds ratio (OR): 0.94; 95 % confidence interval (CI): 0.911-0.975; p=0.001).

Conclusions: This study demonstrates that the novel biomarker copeptin reliably reflects RVF assessed by standardized transthoracic echocardiography compared to NT-proBNP.

背景：评估新型生物标志物和右心室功能障碍的数据有限。正常的右心室功能 (RVF) 可改善心力衰竭患者的预后。因此，与 NT-proBNP 相比，该研究调查了生物标志物和肽素与右心功能之间的关联。

方法：前瞻性纳入接受超声心动图检查的患者。RVF 通过 TAPSE、右心室和心房参数进行评估。排除标准为年龄小于 18 岁、LVEF < 50% 和中度至重度心脏瓣膜病。在超声心动图检查后 72 小时内采集血样进行测量。

结果：共纳入91例患者。和肽素的中值随着 TAPSE 值的降低而显着增加（p = 0.001；RVF I 级：三尖瓣环平面收缩偏移；TAPSE > 24 mm：5.20 pmol/l；II 级：TAPSE 18 - 24 mm：8.10 pmol/l ；III 级：TAPSE < 18 毫米：26.50 pmol/l）。和肽素水平能够区分右心室功能降低的患者，定义为 TAPSE < 18 mm（曲线下面积 (AUC)：和肽素：0.793；p = 0.001；NT-proBNP：0.805；p = 0.0001）。在多元线性回归模型中，和肽素仍与 TAPSE 独立相关（和肽素：T：-4.43；p = 0.0001；NT-proBNP：T：-1.21；p = 0.23）。最后，在多元逻辑回归模型（和肽素：优势比（OR）：0.94；95% 置信区间 (CI)：0.911-0.975；p=0.001）。

结论：本研究表明，与 NT-proBNP 相比，新型生物标志物和肽素可靠地反映了通过标准化经胸超声心动图评估的 RVF。